MODELING THE COST-EFFECTIVENESS OF NOVEL DIRECT ACTING ANTIVIRAL (DAA) TREATMENTS IN PATIENTS CO-INFECTED WITH HEPATITIS C VIRUS (HCV) AND HUMAN IMMUNODEFICIENCY VIRUS (HIV)
Author(s)
McEwan P1, Ward T2, Webster S2, Kalsekar A3, Brenner M4, Yuan Y5
1Health Economics and Outcomes Research Ltd, Cardiff, UK, 2Health Economics and Outcomes Research Ltd, Monmouth, UK, 3Bristol-Myers Squibb, Princeton, NJ, USA, 4Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, UK, 5Bristol-Myers Squibb Pharmaceuticals Ltd, Princeton, NJ, USA
OBJECTIVES: Compared to infection with HCV alone, patients co-infected with HIV have faster disease progression, increased mortality and reduced quality adjusted life expectancy (QALE). The objective of this study was to compare the cost-effectiveness of novel DAA regimens for HCV genotypes (GTs) 1 and 3 (which predominate in the UK) in HCV/HIV co-infected patients. METHODS: A published and validated lifetime HCV Markov model was used to model a cohort of patients (mean age 50 years; 50% female) evenly distributed across fibrosis stages F0–F4, using HIV co-infection specific transition rates . Presented is a comparison of 12 weeks of daclatasvir+sofosbuvir (DCV+SOF) to 24 weeks of sofosbuvir+ribavirin (SOF+RBV) in treatment-naïve patients. Clinical inputs were obtained from pivotal trials: ALLY-2 for DCV+SOF (GT1 SVR: 80/83 [96.39%]; GT3 SVR: 6/6 [100%]) and PHOTON-1/2 for SOF+RBV (GT1 SVR: 182/226 [80.53%]; GT3 SVR: 52/57 [91.23%]). Weekly costs were DCV=£2,043.15, SOF=£2,915.24 and RBV=£66.95. Published disease state costs (UK 2013) and health utility values were used; both costs and benefits were discounted at 3.5%. RESULTS: In GT1 patients, the model predicted that discounted life expectancy (LE) and QALE would increase by 0.52 and 0.69 in DCV+SOF (LE=18.90, QALE=12.37) compared to SOF+RBV (LE=18.37, QALE=11.68), respectively. Overall predicted costs were lower with DCV+SOF (£316,716) versus SOF+RBV (£334,487). In GT3 patients, the model predicted that discounted LE and QALE would increase by 0.36 and 0.44 in DCV+SOF (LE=19.02, QALE=12.52) compared to SOF+RBV (LE=18.66, QALE=12.08), respectively. In GT3, overall predicted costs were also lower with DCV+SOF (£315,416) compared to SOF+RBV (£330,737). CONCLUSIONS: In those co-infected with HIV and GT1 or 3 HCV, 12 weeks of treatment with DCV+SOF was predicted to be dominant (increased QALE with decreased costs) compared to 24 weeks of SOF+RBV.
Conference/Value in Health Info
2015-05, ISPOR 2015, Philadelphia, PA, USA
Value in Health, Vol. 18, No. 3 (May 2015)
Code
PIN67
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Infectious Disease (non-vaccine)